可注射水凝胶在心肌梗死中的应用与进展  

Application and Progress of Injectable Hydrogel in Myocardial Infarction

作　　者：陈广 文英[1] 蒋学俊[1] CHEN Guang;WEN Ying;JIANG Xuejun(Department of Cardiology,Renmin Hospital of Wuhan University,Cardiovascular Research Institute,Wuhan University,Hubei Key Laboratory of Cardiology,Wuhan 430060,Hubei,China)

机构地区：[1]武汉大学人民医院心内科、武汉大学心血管病研究所、心血管病湖北省重点实验室,湖北武汉430060

出　　处：《心血管病学进展》2023年第1期62-66,共5页Advances in Cardiovascular Diseases

基　　金：湖北省重点实验室开放项目(2021KFY050)。

摘　　要：心肌梗死后随着负性心室重塑的进行,心力衰竭是大量患者难以避免的终末状态,其5年死亡率50%以上。作为一种新型生物材料,越来越多的证据表明可注射水凝胶能抑制梗死后心室重塑,改善心功能,为心肌梗死患者提供了一种新的治疗方式,具有广阔的应用前景。现对可注射水凝胶在心肌梗死治疗中的应用及进展做一综述。With the development of negative ventricular remodeling after myocardial infarction,heart failure is an unavoidable end state for a large number of patients,with a 5-year mortality rate of more than 50%.As a novel biomaterial,more and more evidence shows that injectable hydrogel can inhibit ventricular remodeling after infarction,improve cardiac function,provide a new treatment for patients with myocardial infarction,and has broad application prospects.This article reviews the application and progress of injectable hydrogel in the treatment of myocardial infarction.

关 键 词：心肌梗死 心力衰竭 可注射水凝胶 心脏组织工程 

分 类 号：R542.22[医药卫生—心血管疾病]